New Training Requirement for Controlled Substance Rx

new law requires prescribers of controlled substances in schedules II, III, IV, and V to complete a one-time eight-hour training prior to their first registration or renewal of their DEA license, beginning June 27, 2023.

The required training for physicians focuses on “treatment and management of patients with opioid or other substance use disorders, or the safe pharmacological management of dental pain and screening, brief intervention, and referral for appropriate treatment of patients with or at risk of developing opioid or other substance use disorders.”

The AAFP is offering an online CME course on Substance Use Disorders to address these training needs. The sessions were recorded from the AAFP’s Opioid Use Disorder live course and taught by experts who understand the challenges family physicians like you face when helping patients seek treatment. Plus, an additional six sessions are included in this online CME activity. Topics include alcohol use disorder, interpretation of toxicology results, smoking cessation, trauma-informed care, and more—on a schedule that works best for you. Approved for up to 17.75 AAFP Prescribed credits. CME credit approved through October 15, 2024.

There is no charge for AAFP members, new physicians, student or residents. Other health care professionals have a cost of $595 and nonmembers $775.

Curriculum Topics:

  • Alcohol Use Disorder
  • Considering the Patient Perspective
  • Emerging Psychoactive Substances
  • Harm Reduction and Addressing Stigma
  • Harm Reduction Strategies and Programs
  • Intake Assessment and Care Coordination
  • Interpretation of Toxicology Results
  • Managing Common Comorbidities: Sleep, Anxiety, and Depression
  • Office Based Opioid Treatment and Telemedicine
  • Principles of Motivational Interviewing
  • Resources and Next Steps*
  • Screening, Brief Intervention, and Referral to Treatment (SBIRT)
  • Smoking Cessation and e-Cigarettes
  • Stimulant Use Disorder
  • The Evidence Base for Treatment of OUD
  • The Impact of Drug Policy on SUDs
  • Translation to Practice
  • Trauma-Informed Care
  • Treatment of OUD with Buprenorphine, Part 1: Initiation of Treatment
  • Treatment of OUD with Buprenorphine, Part 2: Follow-up Visits and Maintenance
  • What Is Addiction?

Learning Objectives:

At the end of the activity, you will be able to:

  • Implement evidence-based guidelines and principles into the evaluation and treatment of patients with substance use disorders.
  • Demonstrate a patient-centered approach to the care of patients with substance use disorder with attention to destigmatizing language.
  • Discuss harm reduction philosophy and approach to caring for patients and communities.
  • Demonstrate skills and techniques that are appropriate for use in patients with other substance use disorders.

CME Credit Statement:

The AAFP has reviewed Substance Use Disorders and deemed it acceptable for up to 17.75 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 10/15/2021 to 10/15/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The AAFP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Family Physicians designates this Enduring Materials, Self-Study activity for a maximum of 17.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME activities approved for AAFP credit are recognized by the AOA as equivalent to AOA Category 2 credit.

Following this CME activity, participants will have the opportunity to earn an additional two Prescribed credits for participation in each Translation to Practice® exercise. Information on Translation to Practice® will be shared within the activity.